DNMT1 and head and neck squamous cell carcinoma: In this regard, Lee et al. 2022 reported that DNMT1 overexpression correlates with radioresistance in head and neck squamous cell carcinoma (HNSCC), suggesting its potential as a biomarker for predicting the effectiveness of CD47 antibody-based therapy in recurrent HNSCC following radiotherapy [27].